Axim Biotechnologies, Inc. · OTC:AXIM
Axim Biotechnologies — Investor Presentation (May 2020)
27 slides from Axim Biotechnologies's investor presentation, May 2020
Slide 1: Management Presentation
Improving Lives Through Diagnostic and Therapeutic Solutions Management Presentation May 2020
Slide 2: Safe Harbor
SAFE HARBOR This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of AXIM’s management and are subject to significant
Slide 3: About AXIM Biotech
ABOUT AXIM BIOTECH AXIM Biotechnologies is a vertically integrated oncology company developing diagnostic tests for the early detection of cancer, proprietary small molecules drugs not only to treat cancer but also to block metastasis and developing novel antibodies for therapeutic and diagnostic us
Slide 4: Mission Statement
MISSION STATEMENT AXIM is advancing its mission to improve global cancer care through development of novel therapeutics for controlling metastatic cancer spread and diagnostics for early cancer detection. • NOVEL CANCER BIOMARKER DISCOVERY--We have identified a unique enzyme, Quiescin Sulfhydryl Oxi
Slide 5: History of AXIM Biotechnologies
HISTORY OF AXIM BIOTECHNOLOGIES + Acquires Sapphire Biotech, Identifies That SBI-183 Blocks Expanding Company’s Focus to QSOX1 and Obtains Exclusive Founded Targeting Oncology Treatment License to the Compound from in 2014 and Diagnostics the Co-owners AXIM Was One of the First Develops a Diagnostic
Slide 6: QSOX1 Biomarker -- Discovery
QSOX1 BIOMARKER -- DISCOVERY In 2009, the Lake laboratory at Arizona State University Discovers that QSOX1 is Over Expressed in Multiple Tumor Types Colon cancer Pancreatic cancer Lung cancer Prostate cancer
Slide 7: QSOX1 Biomarker -- Shown to be Highly Specific for Cancer
QSOX1 BIOMARKER -- SHOWN TO BE HIGHLY SPECIFIC FOR CANCER + QSOX1 Quiescin Sulfhydryl Oxidase 1 (QSOX1) is an enzyme that forms disulfide bonds (S–S bonds) in tumor-derived proteins. Although QSOX1 is over- expressed in multiple human cancers, it is not expressed or minimally expressed in non-malign
Slide 8: QSOX1 Tumor Target as the Master Regulator of Disulfide Bond Formation
QSOX1 BIOMARKER QSOX1 BIOMARKER ---- SHOWN TUMOR TO BE TARGET ASHIGHLY SPECIFIC THE “MASTER FOR CANCER REGULATOR” OF DISULFIDE BOND FORMATION The extracellular matrix (ECM) is a collection of proteins secreted by tumor cells and tumor associated fibroblasts. The ECM forms a barrier in and around tum
Slide 9: QSOX1-L Biomarker
QSOX1-L BIOMARKER Using proprietary polyclonal antibodies in collaboration with ASU and the Mayo Clinic, we have introduced a prototype diagnostic test that measures levels of QSOX1-L in blood and filed for patent protection. • Our objective now is to introduce a spectrum of diagnostic tools includi
Slide 10: QSOX1-L Biomarker -- Validation Using Blood
QSOX1-L BIOMARKER -- VALIDATION USING BLOOD QSOX1-L Detection QSOX1-L Levels in Different Sample Pools 40.2 23.5 2.3 0.4 0.4 0.4 0.2 BLANK CONTROL SIGMA NORMAL MAYO NORMAL INNOVATIVE SAN DIEGO MAYO CANCER MAYO CANCER POOL, N>1,000 POOL, N=4 RESEARCH BLOOD BANK POOL, N=7 POOL, N=200 NORMAL POOL, NORM
Slide 11: QSOX1-L Biomarker -- Establishing Thresholds in Blood
QSOX1-L BIOMARKER -- ESTABLISHING THRESHHOLDS IN BLOOD QSOX1-L Levels in Individual Samples 12 Normal and 41 Bladder cancer samples run by Lateral Flow assay demonstrate significant separation
Slide 12: QSOX1-L Biomarker -- Product Development
QSOX1-L BIOMARKER – PRODUCT DEVELOPMENT Developing a Rapid Diagnostics Test for QSOX1-L Using Blood Apply drop of blood Read out result in 10 minutes
Slide 13: QSOX1-L Biomarker -- Cancer Diagnostic Test Using Tissue and Proximal Fluids
QSOX1-L BIOMARKER -- CANCER DIAGNOSTIC TEST USING TISSUE AND PROXIMAL FLUIDS • Immunohistochemistry (IHC) Diagnostic Test under development, using proprietary anti-QSOX1-L antibodies for diagnosis of cancer. • The Company’s goal is to complete development of a commercial prototype in 1st quarter, 20
Slide 14: QSOX1 Inhibitor -- Silencing QSOX1 Decreases the Growth Rate of Cancer
QSOX1 INHIBITOR -- SILENCING QSOX1 DECREASES THE GROWTH RATE OF CANCER Genetically suppressing QSOX1 protein expression decreases the growth of MIAPaCa2 pancreatic cell line xenografts in nude mice A) 1600 Untreated B) 1400 C) shScr 1400 shScramble Average Tumor Volume (mm3) sh528 1200 sh742 Average
Slide 15: QSOX1 Inhibitor -- High-Throughput of 50,000 Compounds Identifies SBI-183
QSOX1 INHIBITOR -- HIGH-THROUGHPUT OF 50,000 COMPOUNDS IDENTIFIES SBI-183 RESULTS: SBI-0143183 No prior reports regarding activity as an anti-neoplastic Sapphire Licenses Molecule SBI-183 co-owned by ASU/Mayo Clinic
Slide 16: QSOX1 Inhibitor -- Keys to Becoming a Good Drug Candidate
QSOX1 INHIBITOR -- KEYS TO BECOMING A GOOD DRUG CANDIDATE Inhibitors of QSOX1 need to 1. Inhibition of QSOX1 enzyme 2. Binding to QSOX1 enzyme demonstrate 3 features: 3. Biologically suppress tumor cell invasion 1. Inhibition by SBI-183 2. SBI-183 Binds to QSOX1 KD = 20uM binding Fifield A. et al. 2
Slide 17: SBI-183 -- In Vitro Studies
SBI-183 -- IN VITRO STUDIES 3. SBI-183 Suppresses tumor invasion Triple-negative Sarcomatoid breast cancer kidney cancer Fifield A. et al. 2020 Mol. Cancer Ther.
Slide 18: SBI-183 -- Animal Studies
SBI-183 -- IN VITRO ANIMAL STUDIES SBI-183 suppresses tumor growth in mice Renal Cell Carcinoma UOK117 800 Mouse xenograft model: Kidney Untreated cancer 600 Tumor Volume (mm3) 400 Vehicle 200 ** * 0 Day 0 Day 4 Day 6 Day 9 Day 11 Day 13 Day 15 Day 17 SBI-183 SBI-183 Vehicle Untreated
Slide 19: SBI-183 -- QSOX1 Validated as Cancer Target in Animal Study
SBI-183 -- QSOX1 VALIDATED AS CANCER TARGET IN ANIMAL STUDY SBI-183 suppresses metastasis in a triple negative breast cancer xenograft model (MDA-MB-231-luc) Mice were treated on day 1 by oral gavage (100 mg/kg) for 28 days. 8×1007 Mean Lung Radiance (metastasis) 7×1007 Note: Primary tumor grew at t
Slide 20: SBI-183 -- Hypothesis: Another Compound May Be Better
SBI-183 -- HYPOTHESIS: IF SBI-183 IS EFFECTIVE, ANOTHER COMPOUND MAY BE BETTER! AXIM identifies SPX-1009 - 10X more potent then SBI-183: Triple negative breast cancer Sarcomatoid kidney cancer Day 3 Day 3 .01% Veh .01% Veh Potency increased 10-fold over SBI-183 1250nM SPX-009 1250nM SPX-009
Slide 21: SPX-1009 -- Tenfold More Potent Than SBI-183
SPX-1009 -- TENFOLD MORE POTENT THAN SBI-183 Pre-clinical Results on SPX-1009 as Tumor Antagonist Breast Cancer Lung Cancer No treatment SPX-009 performance in cell-free enzymatic assay SPX-009 performance in 2D breast cancer invasion assay C om pound 9 R epeat 2* 4000 Treatment 3000 F lu o r e s c
Slide 22: Diagnostic Product Pipeline
PRODUCT PIPLINE DIAGNOSTIC PRODUCT PIPELINE PRODUCT PROJECT SITE INDICATION Pre-clinical Phase 1 Phase 2 Phase 3 Diagnostic Test Mayo Clinic Phase 1-Pancreatic Cancer test blood and proximal fluids Phase 2—Screen de-identified longitudinal samples from pancreatic cancer patients to test correlation
Slide 23: Therapeutic Product Pipeline
PRODUCT PIPLINE THERAPEUTIC PRODUCT PIPELINE PRODUCT PROJECT SITE INDICATION Pre-clinical Phase 1 Phase 2 Phase 3 SBI-183/SPX-1009 Sponsored Animal testing to evaluate efficacy of Research each compound ASU/TD2 Labs SBI-183/SPX-1009 TD2 Labs Combination Therapy. Each product will be administered wit
Slide 24: Proven Management Team
PROVEN MANAGEMENT TEAM John W. Huemoeller II Douglas Lake, PhD Chief Catalina Valencia, J.D Dr. Sergei A. Svarovsky, Ph.D., Chief Executive Officer | Clinical Officer | Sapphire Chief Executive Officer | Chief Scientific Officer | AXIM Biotech Biotech Sapphire Biotech Sapphire Biotech Over 35 years
Slide 25: Intellectual Property
INTELLECTUAL PROPERTY Systems and Methods for Rapid Diagnostic for Various Cancers US Provisional Patent Application No. Novel cancer biomarker and clinically relevant QSOX1-L splice variant has been identified as a biomarker of bladder cancer and possibly other cancers in serum. Novel antibodies ha
Slide 26: Intellectual Property (Cont)
INTELLECTUAL PROPERTY (CONT) Anti-Neoplastic Compounds and Methods Targeting QSOX1 and US Provisional Patent Inhibiting Cellular Responses to MET Receptor Application No. Compounds and methods involving inhibition of the enzymatic activity of QSOX1 and methods of inhibiting cellular responses to MET
Slide 27: For further information, please contact
For further information, please contact: info@aximbiotech.com www.aximbiotech.com North American Address: 45 Rockefeller Plaza, 20th Floor, New York, NY 10111, USA +1 844 294 6246
AXIM Biotechnologies — Investor Presentation (May 2020) on 6ix